A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

NCT05972473 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: Aflibercept Ophthalmic
BIOLOGICAL: IBI302

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.